Repository logo
 

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML

Published version
Peer-reviewed

Type

Article

Change log

Authors

Basheer, Faisal 
Giotopoulos, George  ORCID logo  https://orcid.org/0000-0003-1390-6592
Meduri, Eshwar 
Yun, Hayang 
Mazan, Milena 

Abstract

This study demonstrates that EZH2 has stage-specific and diametrically opposite roles during the induction and maintenance stages of AML. However, different transcriptional programs are affected at each stage, identifying mutant EZH2 as a prognostic marker and paradoxically wild-type EZH2 as a potential therapeutic target

Description

Keywords

StemCellInstitute

Journal Title

Journal of Experimental Medicine

Conference Name

Journal ISSN

1540-9538
1540-9538

Volume Title

216

Publisher

Rockefeller University Press
Sponsorship
European Research Council (647685)
Cancer Research UK (25508)
Academy of Medical Sciences (unknown)
Lady Tata Memorial Trust (unknown)
Wellcome Trust (109967/Z/15/Z)
Wellcome Trust (097922/Z/11/Z)
Wellcome Trust (100140/Z/12/Z)
Medical Research Council (MC_PC_12009)
Medical Research Council (MR/R009708/1)
Cancer Research UK (23015)
The Huntly laboratory is funded by CRUK (Programme C18680/A25508), ERC (Grant 647685 COMAL), KKLF, MRC, Bloodwise, the Wellcome Trust (WT) and the Cambridge NIHR BRC. F.B. is a recipient of a Wellcome Trust PhD for Clinicians award. P.G. is funded by the Wellcome Trust (109967/Z/15/Z). We acknowledge the WT/MRC centre grant (097922/Z/11/Z) and support from WT strategic award 100140. Research in the laboratory is also supported by core funding from Wellcome and MRC to the Wellcome-MRC Cambridge Stem Cell Institute. We are grateful to Chiara Cossetti, Gabriela Grondys-Kotarba and Reiner Schulte at the CIMR Flow Cytometry Core for their invaluable help and advice with cell sorting. This research was supported by the Cambridge NIHR BRC Cell Phenotyping Hub. Patient samples were received from the UK NCRI AML trials. The authors declare no competing financial interests.